8 octobre 2025|
AI
|about 2 months agoSwiss Drugmakers Navigate Trump Tariff Challenge with US Investment Plans
Major Swiss pharmaceutical companies commit billions in US investments to avoid potential tariffs, while smaller drug developers face uncertainty.
AI
Generated IllustrationKey Takeaways
AI
- Major Swiss pharmaceutical companies Roche and Novartis are planning large US investments to avoid tariffs
- Switzerland has 226 pharmaceutical manufacturing businesses
- Switzerland has 324 biotech companies active in R&D as of 2024
- The US accounts for 50-60% of Swiss pharmaceutical exports
By The Numbers
$50 billion
Planned investment by Roche in US
$23 billion
Planned investment by Novartis in US over next five years
100%
Proposed tariff rate on patent-protected drugs
They Said
"Larger companies have policy teams working on deals, and they do their own negotiations with the US government"